期刊
BLOOD
卷 118, 期 16, 页码 4338-4345出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-03-340166
关键词
-
类别
资金
- Amgen France for data collection
- Roche France
- Advisory Board for GlaxoSmithKline
Romiplostim, a thrombopoietic agent with demonstrated efficacy against immune thrombocytopenia (ITP) in prospective controlled studies, was recently licensed for adults with chronic ITP. Only France has allowed romiplostim compassionate use since January 2008. ITP patients could receive romiplostim when they failed to respond to successive corticosteroids, intravenous immunoglobulins, rituximab, and splenectomy, or when splenectomy was not indicated. We included the first 80 patients enrolled in this program with at least 2 years of follow-up. Primary platelet response (platelet count >= 50 x 10(9)/L and double baseline) was observed in 74% of all patients. Long-term responses (2 years) were observed in 47 (65%) patients, 37 (79%) had sustained platelet responses with a median platelet count of 106 x 10(9)/L (interquartile range, 75-167 x 10(9)/L), and 10 (21%) were still taking romiplostim, despite a median platelet count of 38 x 10(9)/L (interquartile range, 35-44 x 10(9)/L), but with clinical benefit (lower dose and/or fewer concomitant treatment(s) and/or diminished bleeding signs). A high bleeding score and use of concomitant ITP therapy were baseline factors predicting romiplostim failure. The most frequently reported adverse events were: arthralgias (26%), fatigue (13%), and nausea (7%). Our results confirmed that romiplostim use in clinical practice is effective and safe for severe chronic ITP. This trial was registered at www.clinicaltrials.gov as #NCT01013181. (Blood. 2011; 118(16):4338-4345)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据